Astra Zeneca is in dispute with the European Commission on the export of its COVID vaccine.
Commissioner Kyriakides issued a press statement on Monday concerning vaccine deliveries and the vaccine export transparency scheme. Last Friday, the company AstraZeneca surprisingly informed the Commission and the European Union Member States that it intends to supply considerably fewer doses in the coming weeks than agreed and announced.
This new schedule is not acceptable to the European Union. The European Union has pre-financed the development of the vaccine and the production and wants to see the return.
The European Union wants to know exactly which doses have been produced by AstraZeneca and where exactly so far and if or to whom they have been delivered.
The European Union wants the ordered and pre-financed doses to be delivered as soon as possible, and wants its contract to be fully fulfilled.
The European Union has supported the rapid development and production of several vaccines against COVID-19 with a total of €2.7 billion. They want clarity on transactions and full transparency concerning the export of vaccines from the EU. The dispute continues.
“The 27 European Union Member States are united that AstraZeneca needs to deliver on its commitments in our agreement,” says Kyriades.
“We are in a pandemic. We lose people every day.”
“These are not numbers. They are not statistics. These are persons, with families, with friends and colleagues that are all affected as well.”
“Pharmaceutical companies, vaccine developers, have moral, societal and contractual responsibilities, which they need to uphold.”
“The view that the company is not obliged to deliver because we signed a ‘best effort’ agreement is neither correct nor is it acceptable.”
“We signed an Advance Purchase Agreement for a product which at the time did not exist, and which still today is not yet authorised. And we signed it precisely to ensure that the company builds the manufacturing capacity to produce the vaccine early, so that they can deliver a certain volume of doses the day that it is authorised.”
“The logic of these agreements was as valid then as it is now: we provide a de-risking investment up front, in order to get a binding commitment from the company to pre-produce, even before it gets authorisation.”
“Not being able to ensure manufacturing capacity is against the letter and the spirit of our agreement.”
“We reject the logic of first come, first served. That may work at the neighbourhood butchers, but not in contracts. And not in our Advance Purchase Agreements.”
“There’s no priority clause in the Advance Purchase Agreement.”
“And there’s also no hierarchy of the four production plants named in the Advance Purchase Agreement. Two are located in the EU and two are located in UK.”
“We intend to defend the integrity of our investments and the taxpayers’ money that has been invested.”
“We remain always open to engage with the company to resolve any outstanding issues in the spirit of true collaboration and responsibility.”
“That was always the spirit of our engagement with vaccine manufacturers since last spring.”
“I call on AstraZeneca to engage fully, to rebuild trust, to provide complete information and to live up to its contractual, societal and moral obligations.”
